• No results found

[PDF] Top 20 The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process

Has 10000 "The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process" found on our website. Below are the top 20 most common "The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process".

The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process

The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process

... original ERG exploratory analyses, presented in the ERG reports, appear to have influenced recommendations in a smaller proportion of FADs (47%) than ACDs ...the ERG exploratory ... See full document

9

Pembrolizumab for previously treated advanced or metastatic urothelial cancer : an evidence review group perspective of a NICE single technology appraisal

Pembrolizumab for previously treated advanced or metastatic urothelial cancer : an evidence review group perspective of a NICE single technology appraisal

... The single technology appraisal (STA) process was specifically designed to appraise a single product for a single ...health technology submits a report, which is ... See full document

20

Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective

Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective

... the ERG to meet the NICE reference case ...the impact of SICH following thrombolytic therapy. The evidence used to populate the transition probabilities were considered to be relevant to the ... See full document

20

Venetoclax for treating chronic lymphocytic leukaemia : an evidence review group perspective of a NICE single technology appraisal

Venetoclax for treating chronic lymphocytic leukaemia : an evidence review group perspective of a NICE single technology appraisal

... idelalisib STA (ID764) submitted by Gilead to NICE. The ERG considered the use of the study 116 rituximab arm to be inconsistent with the licensed indication for venetoclax because these patients had ... See full document

9

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

... its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit ... See full document

19

Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

... the type of treatment (TNFi, IL-6, others) and is modelled using survival curves fitted to treatment discontinuation data from the Canadian observational database ...previous NICE technology ... See full document

18

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

... The population modelled was the subgroup of patients in the ATLAS-ACS 2-TIMI 51 trial who were biomarker positive and had not experienced a prior stroke or transient ischaemic attack (TIA). The model consisted of a ... See full document

28

Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

... its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit ... See full document

22

Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

... for NICE to recommend their use within the NHS in England. The NICE Single Technology Appraisal (STA) process usually covers new single health technologies within a ... See full document

26

Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.

Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.

... significant impact. The NICE single technology appraisal (STA) process covers new technologies, within single indications, usually soon after the UK marketing ... See full document

13

Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy : An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy : An Evidence Review Group Perspective of a NICE Single Technology Appraisal

... the single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited Janssen to submit evidence on the clinical and ... See full document

23

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal

... The ERG recognised that the CS included a good-quality systematic review of the efficacy evidence and that the four key RCTs were all good quality and at low risk of ...clinical review found ... See full document

18

Ixazomib for relapsed or refractory multiple myeloma : review from an evidence review group on a NICE single technology appraisal

Ixazomib for relapsed or refractory multiple myeloma : review from an evidence review group on a NICE single technology appraisal

... the Evidence Review Group (ERG) Warwick Evidence was invited to independently review the evidence submitted by the manufacturer of ixazomib, Takeda ... See full document

21

Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

... trial evidence, and this was used to support the use of a constant HR which was applied over the whole model ...The ERG considered that including data up to 72 weeks was consistent with the company’s ... See full document

25

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

... the ERG requested that these be provided by the company where ...The ERG noted that it is generally recommended that at least five studies should be available for a frequentist meta-analysis, whereas the ... See full document

20

Liraglutide for the treatment of type 2 diabetes : a single technology appraisal

Liraglutide for the treatment of type 2 diabetes : a single technology appraisal

... the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s ... See full document

10

The analyses of risk factors for COPD in the Li ethnic group in Hainan, People’s Republic of China

The analyses of risk factors for COPD in the Li ethnic group in Hainan, People’s Republic of China

... This observational study was conducted between January 2012 and December 2014 in the Qicha district in the rural area of Hainan in the People’s Republic of China. We chose Qicha district because it had a stable Li ... See full document

8

NICE guidance : a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium

NICE guidance : a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium

... by NICE on wide consultation, compared to the less extensive approach by SMC, may simply be a function of size of ...the process, though mainly with NHS staff rather than patients and ... See full document

13

Introducing Numerical Analyses in the Early Phases of the Design Process

Introducing Numerical Analyses in the Early Phases of the Design Process

... this type of structure cannot be used. For further finite-elements analyses it is very important to measure or somehow provide a breaking system’s stiffness characteristics and to use appropriate non-linear ... See full document

14

Romiplostim and Eltrombopag for Immune Thrombocytopenia: Methods for Indirect Comparison

Romiplostim and Eltrombopag for Immune Thrombocytopenia: Methods for Indirect Comparison

... above analyses pooled the data on each intervention followed by indirect comparison of pooled values, we planned to under- take a Bayesian metaregression analysis combining results of all trials for both ... See full document

10

Show all 10000 documents...